Status:

COMPLETED

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe an...

Eligibility Criteria

Inclusion

  • male or female subjects ages 18-65 diagnosed with schizophrenia
  • experiencing an acute exacerbation of psychosis
  • has had prior response to antipsychotic therapy within the previous 3 years
  • female subjects must be of non-childbearing potential or must comply with double-barrier protection methods against conception
  • ability of subject or caregiver or legally authorized representative to provide informed consent
  • subjects must be hospitalized at screening and must be willing to remain in the hospital at least 14 days after baseline and must comply with all study events through completion of the study

Exclusion

  • inability of the subject or caregiver or legally authorized representative to provide consent
  • any female subject who is pregnant or breast feeding
  • any subject with concurrent mental illness or disability
  • any subject considered to be a danger to themselves or others
  • recent use of certain antipsychotics or other medications that might interfere with this study's medication
  • abnormal clinical laboratory values
  • presence, or recent history, of serious medical conditions or drug abuse
  • likely allergy or sensitivity to ACP-103, haloperidol, or risperidone, based on known allergies to drugs of the same class
  • any subject who has participated in a prior clinical trial of ACP-103
  • any subject judged by the Principal Investigator to be inappropriate for the study

Key Trial Info

Start Date :

August 1 2005

Trial Type :

INTERVENTIONAL

End Date :

March 1 2007

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT00361166

Start Date

August 1 2005

End Date

March 1 2007

Last Update

March 22 2007

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Cerritos, California, United States, 90703

2

Garden Grove, California, United States, 92845

3

Glendale, California, United States, 91206

4

Paramount, California, United States, 90723